Stocks · News reference

EyePoint Stock Plummets on Mixed Primary Data From Blindness Drug Study

Aug 17, 2026, 2:40 PMVandana Singh

EyePoint reported Phase 3 LUGANO trial results for DURAVYU, highlighting reduced treatment burden despite primary endpoint challenges.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 25, 2026, 2:03 PMAvi Kapoor
Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday
Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.
Read original at benzinga
ABCL CAPR CDLR CRML EIKN
BenzingaAug 19, 2026, 4:26 PMBenzinga Newsdesk
EyePoint shares are trading higher after a Form 4 filing indicated that a company Director bought 10,600 shares at an average price of $4.93 per share.
Read original at benzinga
EYPT
BenzingaAug 18, 2026, 12:39 PMBenzinga Newsdesk
RBC Capital Downgrades EyePoint to Sector Perform, Lowers Price Target to $5
RBC Capital analyst Lisa Walter downgrades EyePoint (NASDAQ:EYPT) from Outperform to Sector Perform and lowers the price target from $37 to $5.
Read original at benzinga
EYPT
BenzingaAug 18, 2026, 12:03 PMBenzinga Newsdesk
Chardan Capital Downgrades EyePoint to Neutral, Lowers Price Target to $5
Chardan Capital analyst Andreas Argyrides downgrades EyePoint (NASDAQ:EYPT) from Buy to Neutral and lowers the price target from $65 to $5.
Read original at benzinga
EYPT